Scaling Scientific R&D with AI Supercomputing Infrastructure — with Thomas Fuchs of Eli Lilly

A growing share of pharmaceutical innovation is now constrained not by scientific imagination, but by the infrastructure required to support AI at scale. In this episode of the AI in Business podcast, Thomas Fuchs, Chief AI Officer at Eli Lilly & Company, joins Matthew DeMello to explore how Lilly's new AI supercomputing platform is reshaping scientific discovery and enterprise operations. The conversation examines how large-scale computing enables more advanced models, secure and usable data environments, and faster scientific iteration across the organization. Learn how brands work with Emerj and other Emerj Media options at go.emerj.com/partner